Analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors using liquid chromatography-electrospray mass spectrometry
- PMID: 11339276
- DOI: 10.1016/s0378-4347(00)00620-4
Analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors using liquid chromatography-electrospray mass spectrometry
Abstract
Employing high-performance liquid chromatography-electrospray mass spectrometry, we describe a new assay for monitoring 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity. Incubations were carried out with HMG-CoA reductase (rat liver), HMG-CoA and NADPH, and terminated by the addition of HCl. The reaction product, mevalonolactone, and internal standard, were extracted with ethyl acetate, dissolved in methanol, and analyzed by LC-MS. Using an isocratic mobile phase of 10% acetonitrile and 0.1% formic acid (flow-rate, 0.2 ml/min), the protonated molecules of mevalonolactone at m/z 131 and internal standard, beta,beta-dimethyl-gamma-(hydroxymethyl)-gamma-butyrolactone, at m/z 145, were detected using selected ion monitoring. The limit of detection was approximately 6.5 pg, and the limit of quantitation was approximately 16.3 pg. Extraction recovery was >90%. The relative standard deviations for intra- and inter-day assays were approximately 4.1+/-2.7 and 9.4+/-3.4%, respectively. Mevalonolactone was examined over a period of 3 days and found to be stable. Using this assay, lovastatin and mevastatin inhibited HMG-CoA reductase activity with IC50 values 0.24+/-0.02 and 2.16+/-0.31 microM, respectively. These methods offer some advantages over those reported previously which employ radiolabeled substrate and products, and should be useful in searching for compounds that could lower serum cholesterol or alter cell growth and differentiation.
Similar articles
-
In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.Toxicol Appl Pharmacol. 1995 Mar;131(1):163-74. doi: 10.1006/taap.1995.1058. Toxicol Appl Pharmacol. 1995. PMID: 7878672
-
Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.Arch Biochem Biophys. 1996 Apr 15;328(2):324-30. doi: 10.1006/abbi.1996.0180. Arch Biochem Biophys. 1996. PMID: 8645011
-
In vivo regulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase: enzyme phosphorylation as an early regulatory response after intragastric administration of mevalonolactone.Proc Natl Acad Sci U S A. 1980 Nov;77(11):6429-33. doi: 10.1073/pnas.77.11.6429. Proc Natl Acad Sci U S A. 1980. PMID: 6256737 Free PMC article.
-
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.Biomed Chromatogr. 2006 Mar;20(3):282-93. doi: 10.1002/bmc.561. Biomed Chromatogr. 2006. PMID: 16143964 Review.
-
Chromatography-mass spectrometry methods for the quantitation of statins in biological samples.J Pharm Biomed Anal. 2007 Jun 28;44(2):379-87. doi: 10.1016/j.jpba.2007.02.008. Epub 2007 Feb 13. J Pharm Biomed Anal. 2007. PMID: 17433599 Review.
Cited by
-
Rapid reverse phase-HPLC assay of HMG-CoA reductase activity.J Lipid Res. 2010 Aug;51(8):2460-3. doi: 10.1194/jlr.D006155. Epub 2010 Apr 24. J Lipid Res. 2010. PMID: 20418539 Free PMC article.
-
Determination of key intermediates in cholesterol and bile acid biosynthesis by stable isotope dilution mass spectrometry.Anal Chem Insights. 2008 Mar 25;3:45-60. doi: 10.4137/aci.s611. Anal Chem Insights. 2008. PMID: 19609389 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical